These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 17243183

  • 1. Atomic resolution crystal structures of HIV-1 protease and mutants V82A and I84V with saquinavir.
    Tie Y, Kovalevsky AY, Boross P, Wang YF, Ghosh AK, Tozser J, Harrison RW, Weber IT.
    Proteins; 2007 Apr 01; 67(1):232-42. PubMed ID: 17243183
    [Abstract] [Full Text] [Related]

  • 2. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
    Tie Y, Boross PI, Wang YF, Gaddis L, Liu F, Chen X, Tozser J, Harrison RW, Weber IT.
    FEBS J; 2005 Oct 01; 272(20):5265-77. PubMed ID: 16218957
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.
    Wang YF, Tie Y, Boross PI, Tozser J, Ghosh AK, Harrison RW, Weber IT.
    J Med Chem; 2007 Sep 06; 50(18):4509-15. PubMed ID: 17696515
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.
    Tie Y, Boross PI, Wang YF, Gaddis L, Hussain AK, Leshchenko S, Ghosh AK, Louis JM, Harrison RW, Weber IT.
    J Mol Biol; 2004 Apr 23; 338(2):341-52. PubMed ID: 15066436
    [Abstract] [Full Text] [Related]

  • 9. Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.
    Tie Y, Wang YF, Boross PI, Chiu TY, Ghosh AK, Tozser J, Louis JM, Harrison RW, Weber IT.
    Protein Sci; 2012 Mar 23; 21(3):339-50. PubMed ID: 22238126
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Insights into the mechanism of drug resistance: X-ray structure analysis of G48V/C95F tethered HIV-1 protease dimer/saquinavir complex.
    Prashar V, Bihani SC, Das A, Rao DR, Hosur MV.
    Biochem Biophys Res Commun; 2010 Jun 11; 396(4):1018-23. PubMed ID: 20471372
    [Abstract] [Full Text] [Related]

  • 12. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir.
    Kagan RM, Shenderovich MD, Heseltine PN, Ramnarayan K.
    Protein Sci; 2005 Jul 11; 14(7):1870-8. PubMed ID: 15937277
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Potent antiviral HIV-1 protease inhibitor GRL-02031 adapts to the structures of drug resistant mutants with its P1'-pyrrolidinone ring.
    Chang YC, Yu X, Zhang Y, Tie Y, Wang YF, Yashchuk S, Ghosh AK, Harrison RW, Weber IT.
    J Med Chem; 2012 Apr 12; 55(7):3387-97. PubMed ID: 22401672
    [Abstract] [Full Text] [Related]

  • 15. Defective hydrophobic sliding mechanism and active site expansion in HIV-1 protease drug resistant variant Gly48Thr/Leu89Met: mechanisms for the loss of saquinavir binding potency.
    Goldfarb NE, Ohanessian M, Biswas S, McGee TD, Mahon BP, Ostrov DA, Garcia J, Tang Y, McKenna R, Roitberg A, Dunn BM.
    Biochemistry; 2015 Jan 20; 54(2):422-33. PubMed ID: 25513833
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Insight into analysis of interactions of saquinavir with HIV-1 protease in comparison between the wild-type and G48V and G48V/L90M mutants based on QM and QM/MM calculations.
    Saen-oon S, Aruksakunwong O, Wittayanarakul K, Sompornpisut P, Hannongbua S.
    J Mol Graph Model; 2007 Nov 20; 26(4):720-7. PubMed ID: 17543558
    [Abstract] [Full Text] [Related]

  • 19. The impact of active site mutations of South African HIV PR on drug resistance: Insight from molecular dynamics simulations, binding free energy and per-residue footprints.
    Ahmed SM, Maguire GE, Kruger HG, Govender T.
    Chem Biol Drug Des; 2014 Apr 20; 83(4):472-81. PubMed ID: 24267738
    [Abstract] [Full Text] [Related]

  • 20. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
    Ohtaka H, Schön A, Freire E.
    Biochemistry; 2003 Nov 25; 42(46):13659-66. PubMed ID: 14622012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.